IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing…Read More